Atara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 8,800 Shares

Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 8,800 shares of the business’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $37.44, for a total transaction of $329,472.00. Following the completion of the transaction, the chief executive officer now owns 808,675 shares in the company, valued at $30,276,792. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Atara Biotherapeutics Inc (NASDAQ ATRA) traded down $2.23 on Monday, reaching $39.47. 1,380,000 shares of the company’s stock were exchanged, compared to its average volume of 1,370,000. The stock has a market capitalization of $1,210.00, a PE ratio of -11.37 and a beta of 2.71. Atara Biotherapeutics Inc has a 52-week low of $11.80 and a 52-week high of $44.00.

A number of research analysts have weighed in on the stock. ValuEngine upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, February 6th. Cowen assumed coverage on shares of Atara Biotherapeutics in a research note on Friday, January 26th. They issued an “outperform” rating on the stock. BidaskClub upgraded shares of Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 23rd. Finally, Canaccord Genuity reiterated a “positive” rating and issued a $70.00 target price (up from $47.00) on shares of Atara Biotherapeutics in a research note on Friday, January 19th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $30.60.

Hedge funds have recently made changes to their positions in the stock. Pacific Heights Asset Management LLC purchased a new stake in shares of Atara Biotherapeutics during the 4th quarter valued at approximately $453,000. Schwab Charles Investment Management Inc. lifted its stake in shares of Atara Biotherapeutics by 16.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 92,974 shares of the biotechnology company’s stock valued at $1,302,000 after buying an additional 13,394 shares in the last quarter. Perceptive Advisors LLC purchased a new stake in shares of Atara Biotherapeutics during the 3rd quarter valued at approximately $581,000. Essex Investment Management Co. LLC purchased a new stake in shares of Atara Biotherapeutics during the 3rd quarter valued at approximately $429,000. Finally, Vanguard Group Inc. lifted its stake in shares of Atara Biotherapeutics by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock valued at $11,842,000 after buying an additional 13,952 shares in the last quarter. Institutional investors own 69.58% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/12/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-8800-shares.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply